-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Hyperuricemia is a causative factor in urate deposition diseases such as urolithiasis and gouty arthritis.
In order to further compare the efficacy and safety of dotinurad and benzbromarone, the researchers conducted a 14-week randomized, multicenter, double-blind phase 3 study.
The patients were randomly divided into groups (dotinurad: 102, benzbromarone: 99) and received dotinurad 2 mg or benzbromarone 50 mg, once a day for 14 weeks.
The results showed that from baseline to the last visit, the average percentage changes in serum uric acid levels in the dotinurad group and benzbromarone group were 45.
In summary, the results of this study show that in Japanese patients with hyperuricemia, whether or not they have gout, dotinurad 2 mg is non-inferior to benzbromarone 50 mg in reducing serum uric acid.
Original source:
Julio Núñez, Pau Llàcer, et al.
ncbi.
nlm.
nih.
gov/31980978/" target="_blank" rel="noopener">CA125-Guided Diuretic Treatment Versus Usual Care in Patients With Acute Heart Failure and Renal Dysfunction in this message